Zobrazeno 1 - 10
of 373
pro vyhledávání: '"Åslaug Helland"'
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 22, Iss , Pp 15-21 (2020)
Background: Lymphopenia during radiotherapy (RT) may have an adverse effect on treatment outcome. The aim of this study is to investigate associations between lymphopenia and RT parameters in patients with advanced lung cancer. Moreover, to investiga
Externí odkaz:
https://doaj.org/article/0f57ef78bc6e4ffc909a7cced857f0b1
Autor:
Azadeh Abravan, Hanne Astrid Eide, Ingerid Skjei Knudtsen, Ayca Muftuler Løndalen, Åslaug Helland, Eirik Malinen
Publikováno v:
Clinical and Translational Radiation Oncology, Vol 4, Iss C, Pp 57-63 (2017)
Purpose: To investigate effects of radiotherapy (RT) and erlotinib on pulmonary glucose uptake using 2-deoxy-2-(18F)fluoro-D-glucose (18F-FDG) positron emission tomography (PET) during and after treatment of non-small cell lung cancer (NSCLC) and to
Externí odkaz:
https://doaj.org/article/d9fba4383eb842a6beeb1137af3382be
Autor:
Yngvar Nilssen, Odd Terje Brustugun, Lars Fjellbirkeland, Åslaug Helland, Bjørn Møller, Sissel Gyrid Freim Wahl, Steinar Solberg
Publikováno v:
BMC Pulmonary Medicine, Vol 24, Iss 1, Pp 1-10 (2024)
Abstract Background The main focus on the characteristics of malignant lung tumours has been the size, position within the lobe, and infiltration into neighbouring structures. The aim of this study was to investigate the distribution and characterist
Externí odkaz:
https://doaj.org/article/5875a883bc094aa79f00eb35ae725d73
Autor:
Hanne Marte Nymoen, Tine Norman Alver, Henrik Horndalsveen, Hanne Astrid Eide, Maria Moksnes Bjaanæs, Odd Terje Brustugun, Bjørn Henning Grønberg, Vilde Drageset Haakensen, Åslaug Helland
Publikováno v:
Frontiers in Oncology, Vol 14 (2024)
BackgroundRadiotherapy (RT) can be used to reduce symptoms and maintain open airways for patients with non-small cell lung cancer when systemic treatment is not sufficient. For some patients, tumor control is not achieved due to radioresistance. Conc
Externí odkaz:
https://doaj.org/article/e8ccea5765124b9cb6e2d11e1fe3772e
Autor:
Elisa Bjørgo, Gro L. Fagereng, Hege G. Russnes, Sigbjørn Smeland, Kjetil Taskén, Åslaug Helland
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Externí odkaz:
https://doaj.org/article/ccbf3147c396479db17778c1fcc62cf3
Autor:
Ulrik Ringborg, Joachim vonBraun, Julio Celis, Michael Baumann, Anton Berns, Alexander Eggermont, Edith Heard, Manuel Heitor, Mammen Chandy, Chien‐Jen Chen, Alberto Costa, Francesco De Lorenzo, Edward M. De Robertis, Frederick Charles Dubee, Ingemar Ernberg, Mariya Gabriel, Åslaug Helland, Rui Henrique, Bengt Jönsson, Olli Kallioniemi, Jan Korbel, Mechthild Krause, Douglas R. Lowy, Olivier Michielin, Peter Nagy, Simon Oberst, Vincenzo Paglia, M. Iqbal Parker, Kevin Ryan, Charles L. Sawyers, Joachim Schüz, Katherine Silkaitis, Eric Solary, David Thomas, Peter Turkson, Elisabete Weiderpass, Huanming Yang
Publikováno v:
Molecular Oncology, Vol 18, Iss 2, Pp 245-279 (2024)
Analyses of inequalities related to prevention and cancer therapeutics/care show disparities between countries with different economic standing, and within countries with high Gross Domestic Product. The development of basic technological and biologi
Externí odkaz:
https://doaj.org/article/aed58f51906b40f3875630c0b7d33c89
Autor:
Kjetil Taskén, Soemeya F. Haj Mohammad, Gro Live Fagereng, Ragnhild Sørum Falk, Åslaug Helland, Sahar Barjesteh van Waalwijk van Doorn-Khosrovani, Katarina Steen Carlsson, Bettina Ryll, Katriina Jalkanen, Anders Edsjö, Hege G. Russnes, Ulrik Lassen, Ebba Hallersjö Hult, Iwona Lugowska, Jean-Yves Blay, Loic Verlingue, Edvard Abel, Maeve A. Lowery, Matthew G. Krebs, Kristoffer Staal Rohrberg, Kristiina Ojamaa, Julio Oliveira, Henk M.W. Verheul, Emile E. Voest, Hans Gelderblom
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation o
Externí odkaz:
https://doaj.org/article/a341b8825c7a4512be06dc2a4bf54da1
Autor:
Katarina Puco, Gro Live Fagereng, Sigmund Brabrand, Pitt Niehusmann, Egil Støre Blix, Eli Sihn Samdal Steinskog, Åse Haug, Cecilie Fredvik Torkildsen, Irja Alida Oppedal, Sebastian Meltzer, Åsmund Flobak, Kajsa Anna Margareta Johansson, Line Bjørge, Geir Olav Hjortland, Astrid Dalhaug, Jo-Åsmund Lund, Bjørnar Gilje, Marte Grønlie Cameron, Randi Hovland, Ragnhild S. Falk, Sigbjørn Smeland, Hege Elisabeth Giercksky Russnes, Kjetil Taskén, Åslaug Helland
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background and purpose: In Norway, comprehensive molecular tumour profiling is implemented as part of the public healthcare system. A substantial number of tumours harbour potentially targetable molecular alterations. Therapy outcomes may improve if
Externí odkaz:
https://doaj.org/article/7e579b1a8041406e8bd9367ceab85308
Autor:
Rosalba Miceli, Hanna Eriksson, Giuseppe Lo Russo, Salvatore Alfieri, Maria Moksnes Bjaanæs, Filippo Pietrantonio, Loris De Cecco, Arsela Prelaj, Claudia Proto, Johan Franzén, Deirdre McDonnell, José Javier Berenguer Pina, Teresa Beninato, Laura Mazzeo, Patrizia Giannatempo, Elena Verzoni, John Crown, Åslaug Helland, Alexander Eustace
Publikováno v:
Acta Oncologica, Vol 63, Iss 1 (2024)
Background: Immune checkpoint inhibitors (ICIs) have significantly improved outcomes in various cancers. ICI treatment is associated with the incidence of immune-related adverse events (irAEs) which can affect any organ. Data on irAEs occurrence in r
Externí odkaz:
https://doaj.org/article/104cb507efb6499da6d34e4000166944
Autor:
Åslaug Helland, Tor Åge Myklebust, Simona Conte, Line Elmerdahl Frederiksen, Jørgen Aarøe, Espen Enerly
Publikováno v:
Cancer Treatment and Research Communications, Vol 38, Iss , Pp 100785- (2024)
Introduction: Testing for mutations of epidermal growth factor receptor (EGFR) is crucial to identify non-small cell lung cancer (NSCLC) patients eligible for treatment with EGFR tyrosine kinase inhibitors (EGFR-TKIs); This study aims to describe EGF
Externí odkaz:
https://doaj.org/article/824755a3f6874d2d851a8248aeae72cf